PureTech Health Celebrates FDA Approval of Cobenfy: A Milestone in Schizophrenia Treatment
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has achieved a significant milestone with the FDA's recent approval of Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults.
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the treatment via Karuna Therapeutics deal for $330 per share in cash for a total equity value of $14 billion.
Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug
Bristol-Myers Squibb (BMY) shares rose early Friday as the biopharmaceutical company obtained approval from the US Food and Drug Administration for its Cobenfy drug to treat schizophrenia in adults. The oral medication is designed to treat schizophrenia by targeting cholinergic receptors instead of dopamine receptors,
FDA Approves KarXT To Treat Schizophrenia; PureTech Health Gets $29 Mln Milestone Payment
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March of 2024. Royalty Pharma had acquired an interest in PureTech's royalty in KarXT.
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Cranswick flags strong annual results, PureTech schizophrenia treatment gets US approval
London open The FTSE 100 is expected to open eight points higher on Friday, having closed up 0.2% on Thursday at 8,284.91.
PureTech Health celebrates KarXT approval by FDA for schizophrenia
PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone triggers payments to it totalling USD29 million under agreements with Royalty Pharma and Karuna Therapeutics,
Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult Schizophrenia Treatment
Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium
FDA approves 1st new drug to treat schizophrenia in more than 30 years
This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a new alternative to the antipsychotic medications peo
First Novel Schizophrenia Treatment in Decades Gains FDA Approval
The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration approved the drug on Thursday, greenlighting the first of a new class of treatments that could help stabilize patients’ symptoms without the uncomfortable side effects that accompany existing antipsychotics.
First New Schizophrenia Treatment Approach In Decades Gets FDA Approval
The US Food and Drug Administration (FDA) has just approved a new drug for the treatment of schizophrenia. Marketed under the name Cobenfy, the medication combines two different drugs that together target a totally different mechanism in the brain than conventional antipsychotics,
Security22h
PureTech Systems awarded contract to help secure critical international waterway
PureActiv will deploy across multiple locations to detect unauthorized access as ships travel through the waterway system.
FTSE 250 movers: Burberry gains on China boost
Stocks in China got a boost after the central bank cut its main policy rate and financial institutions’ reserve requirement ratio in a bid to boost lending. The People’s Bank of China cut the ...
Exchange 4 Media9h
Agility and AI: How digital marketing agencies are redefining brand building
Industry leaders came together at the e4m IDAC Summit 2024 to discuss the shifts in the marketing landscape and the ...
Security18h
PureTech Systems adds Access Control Auto-Verify to eliminate nuisance alarms
The PureActiv enhancement automatically validates access control security violations and dismisses nuisance alarms.
French inflation ‘crash’ raises pressure for interest rate cuts
Christine Lagarde is under pressure to ramp up the pace of interest rate cuts in the eurozone after French and Spanish ...